EE680 Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.945
https://www.valueinhealthjournal.com/article/S1098-3015(23)04075-5/fulltext
Title :
EE680 Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04075-5&doi=10.1016/j.jval.2023.09.945
First page :
Section Title :
Open access? :
No
Section Order :
10436